The document discusses several key issues regarding intellectual property rights (IPR) and biotechnology innovations:
1) Article 27.3 of the TRIPS Agreement requires WTO members to extend patent protection to microorganisms and microbiological processes. Members must also protect plant varieties through patents, an effective sui generis system, or a combination.
2) The sui generis option allows governments flexibility to implement alternatives to patents, such as plant breeders' rights, in accordance with the Convention on Biological Diversity.
3) Biotech companies rely heavily on patents, investing 45% of annual income into R&D. Patents are an important incentive for continued innovation in biotechnology. However, excessive
Copyright:
Attribution Non-Commercial (BY-NC)
Available Formats
Download as PPT, PDF, TXT or read online from Scribd
The document discusses several key issues regarding intellectual property rights (IPR) and biotechnology innovations:
1) Article 27.3 of the TRIPS Agreement requires WTO members to extend patent protection to microorganisms and microbiological processes. Members must also protect plant varieties through patents, an effective sui generis system, or a combination.
2) The sui generis option allows governments flexibility to implement alternatives to patents, such as plant breeders' rights, in accordance with the Convention on Biological Diversity.
3) Biotech companies rely heavily on patents, investing 45% of annual income into R&D. Patents are an important incentive for continued innovation in biotechnology. However, excessive
The document discusses several key issues regarding intellectual property rights (IPR) and biotechnology innovations:
1) Article 27.3 of the TRIPS Agreement requires WTO members to extend patent protection to microorganisms and microbiological processes. Members must also protect plant varieties through patents, an effective sui generis system, or a combination.
2) The sui generis option allows governments flexibility to implement alternatives to patents, such as plant breeders' rights, in accordance with the Convention on Biological Diversity.
3) Biotech companies rely heavily on patents, investing 45% of annual income into R&D. Patents are an important incentive for continued innovation in biotechnology. However, excessive
Copyright:
Attribution Non-Commercial (BY-NC)
Available Formats
Download as PPT, PDF, TXT or read online from Scribd
The document discusses several key issues regarding intellectual property rights (IPR) and biotechnology innovations:
1) Article 27.3 of the TRIPS Agreement requires WTO members to extend patent protection to microorganisms and microbiological processes. Members must also protect plant varieties through patents, an effective sui generis system, or a combination.
2) The sui generis option allows governments flexibility to implement alternatives to patents, such as plant breeders' rights, in accordance with the Convention on Biological Diversity.
3) Biotech companies rely heavily on patents, investing 45% of annual income into R&D. Patents are an important incentive for continued innovation in biotechnology. However, excessive
Copyright:
Attribution Non-Commercial (BY-NC)
Available Formats
Download as PPT, PDF, TXT or read online from Scribd
stipulates that WTO members extend patent protection to micro organisms and non-biological and micro-biological processes c Members are also requested to protect plant varieties either through patent or an effective R R or combination of both and they are due for review. Plant Breeders rights
c The sui generis option is the
key.In Latin it means µof it¶s own kind¶ c TRIPS allows this««« c But US and other patent holding countries would like to eliminate this provision as it allows for alternatives to patent 2 R acts as a key to allow government to implement another International Treaty.The Convention on Biological Diversity ènowledge Intensive Biotech Industry cannot do without patents
c Companies plough some 45% of
their annual income into R&D c Nearly half the value of the industry is embedded in it¶s intellectual capital c
c
c ence Biotech companies feel that their heavy investment in knowledge is worth it.ence patenting is important to researchers.It acts as an incentive for them to continue researching c While protection of IP is essential excessive protection can restrict consumption limit product availability and maintain unnecessary high prices c
c But at present the dimension of IPR are becoming unimaginable from what it was in 1950¶s and 1960¶s c Application of those rules to the biotechnology innovation has become a major public challenge c thics are used to justify patent exclusion in every country in OCD urope as well as in Japan,èorea and New Zealand c Only Australia, Canada and US do not recognize such general grounds for exclusion c As ethics involved to prevent uman cloning and animal suffering due to experimentation. WTO & GMO c After 1994 one of the issue that was not a high priority at that time but is very much so now is the trade of genetically engineered or modified organisms c GMO foods or seeds for food crops and other products with altered DNA. The industries ties to GMO are affected by 3 significant agreements c AOA c SPS Agreement c Agreement on TRIPS WTO membership remains vertically divided on the issue of Trade in GMO¶s
! &
"#$%
'' '"#$%
Unless the potential effects are known on GMO¶s
ban should continue Mandatory labeling to segregate GM food and Organic Food Consumers should be able to make informed choice c Consumers attitude to risk and government approaches to food safety and quality vary significantly from country to country.